HANTZ FINANCIAL SERVICES, INC.
Position in HALO — Halozyme Therapeutics, Inc.
CIK 1071061
SOUTHFIELD, MI
Position in HALO
as of Mar 31, 2026
· filed May 1, 2026
Position Value
$3,986,701
-$1,256,843 QoQ
Shares Held
61,685
-20.8% QoQ
Ownership
0.052%
of shares outstanding
% of Portfolio
0.14%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Sep 2024
7 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in HALO Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026HANTZ FINANCIAL SERVICES, INC. holds $27,021,973 across 66 Biotechnology names. HALO ranks #3 (14.8% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
17,807 | $7,951,537 | |
| 2 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
17,673 | $5,847,465 | |
| 3 | HALO |
Halozyme Therapeutics, Inc.
This page
|
61,685 | $3,986,701 | |
| 4 | ARGX |
Argenx SE
|
1,434 | $1,047,178 | |
| 5 | ROIV |
Roivant Sciences Ltd.
|
31,870 | $882,799 | |
| 6 | TECH |
BIO-TECHNE Corp
|
16,753 | $875,511 | |
| 7 | BMRN |
Biomarin Pharmaceutical Inc
|
11,338 | $640,483 | |
| 8 | JAZZ |
Jazz Pharmaceuticals plc
|
3,293 | $622,541 |
All Filings in HALO
Export CSV
7 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,986,701 | 61,685 | Shares | Sole | 2026-05-01 | |
| 2025-12-31 | $5,243,544 | 77,913 | Shares | Sole | 2026-02-09 | |
| 2025-09-30 | $7,182,479 | 97,934 | Shares | Sole | 2025-11-05 | |
| 2025-06-30 | $7,011,255 | 134,780 | Shares | Sole | 2025-08-04 | |
| 2025-03-31 | $9,685,337 | 151,784 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $6,641,287 | 138,910 | Shares | Sole | 2025-01-23 | |
| 2024-09-30 | $9,259,829 | 161,772 | Shares | Sole | 2024-11-14 | |
| No filing history on record for this holder in this stock. | ||||||